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INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
  
 Non cirrhotic intrahepatic portal hypertension (NCIPH) is traditionally named as 
non cirrhotic portal fibrosis (NCPF) in India. It is more prevalent in developing countries 
and it is a commonly encountered clinical entity. As per data from our centre, cryptogenic 
cirrhosis is the commonest cause for portal hypertension, 39 to 48% of patients labeled as 
cryptogenic cirrhosis turn out to be NCIPH after liver biopsy (1,2) 
NCIPH usually appears to have a benign course, however patients may worsen to 
a stage requiring liver transplantation(3). The exact etiopathogenesis of this common 
condition is still unknown. There are various hypotheses like infective, immunogenic, 
prothrombotic and trace elements exposure. 
There are data to support the association between gut disorders, prothrombotic 
conditions and NCIPH. Eapen et al found 16% of NCIPH patients to have celiac disease 
and 3% to have ulcerative colitis(4). Hillaire et al found association between 
prothrombotic conditions like myeloproliferative disorders and NCIPH(5). Considering 
the above associations, we postulate a hypothesis that a combined effect of gut disorders 
and prothrombotic conditions lead to portal microangiopathy. 
Gut disorders like celiac disease are commonly associated with altered intestinal 
permeability called as leaky gut(6). This leakiness can lead to migration of bacteria and 
bacterial products from the gut which is termed as bacterial translocation(7). In the 
presence of a preexisting prothrombotic state in portal circulation, these gut factors could 
trigger a thrombotic event. 
It is well known that in liver cirrhosis, altered intestinal permeability and bacterial 
translocation happen, particularly in patients with ascites and advanced cirrhosis(8). 
Bacterial translocation has been proposed to play a role in progression of liver fibrosis(9) 
However there is no data on association between NCIPH and bacterial translocation. 
ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 
motif, member 13) is a protease, action of which is to cleave von Willebrand factor 
multimers  released from activated/ damaged endothelium. If there is a deficiency in the 
ADAMTS13 activity, ultralarge vWF accumulate and cause platelet aggregation under 
shear stress that results in microangiopathy called thrombotic thrombocytopenic purpura 
(TTP). ADAMTS13 is exclusively synthesized from stellate cells, so the portal blood is 
expected to have the lowest concentration due to its upstream relationship to stellate 
cells(10).  
It is  documented that in liver cirrhosis, with advancing liver disease ADAMTS13 
activity comes down proportionately along with a corresponding increase in vWF activity 
and multimers(11). Mackie et al analyzed the ADAMS13 activity in NCIPH patients and 
found that irrespective of the severity of liver dysfunction, NCIPH patients have low 
ADAMTS13 activity(12) 
Based on the above literature we designed our hypothesis as follows: A 
combination of gut disorders which make the gut leaky for gut derived factors to enter 
circulation and the preexisting ADAMTS13 deficiency, act together in the pathogenesis 
of portal microangiopathy. 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
AIM OF THE STUDY 
 
 
 
 
 
Hypothesis: 
  A combination of gut disorders which make the gut leaky for gut derived factors 
to enter the portal circulation and a preexistent prothrombotic state in portal circulation 
due to ADAMTS13 deficiency, act together to produce obliterative portal 
microangiopathy in Non cirrhotic intrahepatic portal hypertension ( NCIPH) 
 
Aim of the study: 
Aim 1- To study the association between gut disorders, bacterial translocation and 
NCIPH. 
Aim 2- To assess the status of ADAMTS13 (a disintegrin and metalloprotease with a 
thrombospondin type 1 motif, member 13) in NCIPH patients and compare with that of 
controls. 
 
 
 
 
 
  
 
 
 
REVIEW OF LITERATURE 
 
 
 
 
 
  
Non Cirrhotic Portal Hypertension means portal hypertension in the absence of 
cirrhosis. This can be either intrahepatic or extrahepatic. Non cirrhotic Intrahepatic Portal 
Hypertension (NCIPH) is a broad terminology encompassing multiple entities 
characterized by presence of intrahepatic portal hypertension without cirrhosis(13). These 
entities include Non cirrhotic portal fibrosis (NCPF), Idiopathic portal hypertension 
(IPH), Nodular regenerative hyperplasia (NRH), partial nodular transformation, 
incomplete septal sclerosis, hepatoportal sclerosis and benign intrahepatic portal 
hypertension.  
Asian Pacific Association for the Study of the Liver (APASL), Working Party on 
Portal Hypertension defined NCIPH as  
“A disease of uncertain etiology, characterized by periportal fibrosis and 
involvement of small and medium branches of the portal vein; resulting in the 
development of portal hypertension. The liver functions and structure primarily remain 
normal.”(14) 
 
Historical background: 
In early 1960s, various researchers from many parts of the world recognized the 
presence of obliterative portal venopathy in patients with non cirrhotic disease presenting 
with bleeding varices. (15–17) Since then the understanding of the disease improved 
significantly. This distinct clinico-pathological entity was termed as noncirrhotic portal 
fibrosis (NCPF) in India and as idiopathic portal hypertension (IPH) in Japan. Several 
different terminologies have been described; these probably represent the varied spectrum 
of the same disease. 
 
Epidemiology: 
 NCIPH has been reported to clinically manifest in 3
rd
 to 4
th
 decade of life. Reports 
from India have shown either no gender predilection or a male predominance, where as 
reports from Japan showed female preponderance. Mainly the disease affects 
socioeconomically disadvantaged people(18) This may explain the decreasing incidence  
of this entity in developed countries. 
 However it is still a commonly encountered clinical condition in developing 
countries. Studies from our centre document NCIPH to be a common cause for 
cryptogenic intrahepatic portal hypertension. Retrospective analysis of portal 
hypertensive patients who underwent liver biopsy, showed that 48%( 30/62) of  patients 
labeled as cryptogenic cirrhosis turned out to have NCIPH after liver biopsy(1)  
Prospective analysis of 610 portal hypertensive patients showed cryptogenic chronic liver 
disease to be the commonest cause of portal hypertension. Among the cryptogenic 
patients who underwent liver biopsy, 39% had NCIPH , not the true cryptogenic 
cirrhosis(2). Thus the prevalence of NCIPH was 39 to 48% among the patients who 
underwent liver biopsy with a clinical diagnosis of cryptogenic cirrhosis. 
 
 
 
 
Clinical presentation and Natural history: 
 Clinical presentations are mainly related to portal hypertension, either bleeding or 
non bleeding varices, splenomegaly or hypersplenism. Liver function remains well 
preserved for long time. Majority of patients tend to have pancytopenia particularly 
thrombocytopenia. Liver may appear normal or nodular in ultrasonography. Esophageal 
or gastric varices are noted in >95% of patients. Hepatic venous pressure gradient can be 
normal or slightly elevated. 
 Generally NCIPH patients have good prognosis(19,20). However the disease can 
progress to a stage requiring liver transplantation. This has been convincingly 
demonstrated by study of explant livers from clinically cirrhotic individuals(3) Eapen et 
al reported progression to liver failure in 53% of NCIPH patients over a median follow 
up period of 88 months, indicating that NCIPH is not always a benign disease(4) 
 
Pathophysiology: 
 The histological hallmark of NCIPH is obliterative portal venopathy as termed by 
Nayak and Ramalingaswami in 1969(21) The denominator for the varied morphological 
changes noticed in NCIPH is the occlusive portal microangiopathy(5). There is portal and 
periportal fibrosis which lead to alteration in intrahepatic portal blood flow. Aberrant 
ectatic vessels can be seen representing a process similar to collateral formation(22). 
Above changes are typically patchy. Subcapsular atrophy and nodular hypertrophy 
happen due to the patchy insufficiency in portal supply(23). Long standing insufficiency 
results in phlebosclerosis of hepatic vein branches(24). 
 
 Liver biopsy and documentation of absence of advanced fibrosis or cirrhosis is the 
most important requirement to differentiate NCIPH from cirrhosis. 
 
 
Figure 1: Densely fibrotic portal tract with  
occlusion of portal vein 
    
 
  
Figure 2: Ectatic portal vein branch 
 
 
Etiopathogenesis: 
 Etiology is unknown. Many different mechanisms like Infective, Immunogenic, 
Prothrombotic and exposure to trace chemicals are proposed. 
 
 
Figure 4: Nodular regenerative hyperplasia 
 
 
 
 
 
Figure 3: Two abnormally opposed portal 
tracts without portal veins 
Infective hypothesis: 
 Since NCIPH is a disease prevalent in developing countries among low socio 
economic population, infective hypothesis is postulated. Repeated diarrheal disease, 
neonatal umbilical sepsis or other intraabdominal infections are likely to result in portal 
pyemia which in turn can lead to portal pylephlebitis, thrombosis, sclerosis and 
obstruction of small portal vein branches(25). This hypothesis is supported by animal 
models , where NCIPH like pathology had been demonstrated after intraportal injection 
of nonpathogenic E.coli(26) 
 
Immunogenic hypothesis: 
 There is some evidence that there may be deranged immune response or 
autoimmunity playing role in NCIPH(27) 
 
Exposure to trace chemicals: 
 Chronic arsenic, vinyl chloride exposures have been described to be associated 
with development of NCPF(28,29) Other factors like hypervitaminosis A, chronic 
exposure to azathioprine, methotrexate, 6-mercaptopurine, didanosine have also been 
observed to have relation with NCIPH. 
 
Hypercoagulability: 
 Hillaire et al reported strong association of prothrombotic conditions with 
NCIPH. In this study  extensive prothrombotic work up was done in 23 patients, 12 out of 
23( 48%) were found to have associated one or more prothrombotic conditions- five 
patients had myeloproliferative disorder, four had protein S deficiency, one had protein C 
deficiency, five had high anticardiolipin antibody. On long term follow up 13 patients 
developed extrahepatic portal venous thrombosis supporting the existence of 
prothrombotic status. The authors concluded that anticoagulant therapy is to be strongly 
considered in NCIPH patients(5).  
In spite of many hypothesis and supporting evidence, the exact etiology and 
pathogenesis of changes in NCIPH are not yet known, due to which the management of 
patients with NCIPH is only symptomatic and supportive. 
Researchers have found association of NCIPH with gut diseases as well as various 
prothrombotic conditions. These concepts led to derivation of new hypothesis for the 
etiopathogenesis of the entity. 
 
Gut disorders and NCIPH: 
 Various studies have documented possible association between NCIPH and gut 
disorders, particularly celiac disease. In 2006, Sharma et al from India reported two cases 
of celiac disease with coexistent NCPF, and they postulated autoimmune mechanisms to 
drive the pathogenesis of the two conditions together(30). Similar association of celiac 
disease with Nodular regenerative hyperplasia had also been demonstrated(31,32) 
Zamani et al from Iran reported a case of  decompensated NCIPH associated with    
celiac disease complicated with ulcerative jejunoileitis and intestinal lymphoma(33)  
 A search for the coexistent gut disorders among 34 NCIPH patients was made by 
Eapen at al(4). Among 31 patients tested for celiac serology by IgA anti tissue 
transglutaminase/ anti endomysial antibodies, five (16%) tested positive for celiac 
serology and also had duodenal histology consistent with celiac disease. Three patients 
(9%) had ulcerative colitis. 
 Data from our centre support the high prevalence of celiac disease among 
cryptogenic chronic liver disease patients (22% - 11 out of 51). Seven patients out of 
these eleven underwent liver biopsy and five of them were found to have NCIPH. 
 Since the pathology in NCIPH is primarily confined to the portal circulation 
characterized by selective portal microcirculatory obliteration, causative factor may be 
derived from the gut since the portal circulation forms the first filter for gut derived 
factors. In the presence of gut disorders, there is a potential for various gut derived 
factors like bacteria, bacterial products, inflammatory cytokines, immunoglobulins etc. to 
enter portal circulation. 
 
Prothrombotic conditions and NCIPH: 
 As mentioned earlier, various hypercoagulable conditions have been found to be 
coexisting in NCIPH patients(5) Eapen et al demonstrated elevated anticardiolipinA 
antibody among patients with NCIPH when compared to patients with Budd- Chiari 
syndrome. Elevation in anticardiolipinA antibody was found to be significantly higher 
than that of anticardiolipinG and anticardiolipinM antibodies. IgA antibodies form the 
candidate gut derived antibodies, hence the authors postulated that the prothrombotic 
factors in NCIPH are probably gut derived and affect the portal circulation which is the 
first filter for gut derived factors(4). 
  
 
Elevated IgA anticardiolipin antibodies in patients with celiac disease and nodular 
regenerative hyperplasia has been described by many authors(31,32)  
Selective obliteration of portal microcirculation may be either due to gut derived 
prothrombotic factors entering the portal system culminating in the thrombotic event or a 
preexistent prothrombotic state in portal circulation with gut derived factors triggering 
the thrombotic event. 
 Mackie et al hypothesized that an imbalance in von Willebrand factor (VWF) and 
ADAMTS13 (a disintegrin and metalloprotease with a thrombospondin type 1 motif, 
member 13) which is observed in Thrombotic thrombocytopenic purpura(TTP), if 
confined to portal circulation  at the point where hepatic arterial pressures are 
superimposed, would provide a mechanism for development of portal microangiopathy 
similar to systemic microangiopathy occurring in TTP(12). 
 In this study, 18 NCIPH patients and 25 controls with chronic liver disease of 
other etiologies were included. Cases and controls were comparable with regard to the 
severity of liver disease. ADAMTS13 activity assay, ADAMTS13 antigen levels, 
ADAMTS13 antibody levels, VWF antigen, activity and VWF multimer levels were 
measured.  
It was observed that ADAMTS13 activity and antigen levels were significantly 
reduced in cases when compared to controls. Marked reduction in activity (activity <5%) 
was noted in 28% of cases and in none among the controls. Corresponding reduction in 
antigen levels was also observed. Notably most of the NCIPH patients had low platelet 
count which was disproportionate to MELD score unlike the disease controls, which  
 
indicates that they may be additional mechanisms for thrombocytopenia in NCIPH 
patients. The study looked for possible presence of ADAMTS13 antibodies/inhibitors as 
the cause for low activity, however there was no difference between the cases and 
controls and there was no correlation between the presence of antibodies and low activity. 
One third of the patients had ultra large VWF multimers. VWF Ag and activity 
were either normal or increased in both cases and controls. There was a correlation 
between VWF activity and MELD in both cases and controls. 
 Sustained low ADAMTS13 activity was noticed in four NCIPH patients over a 
period of six weeks to eleven months. 
 Authors concluded sustained ADAMTS13 deficiency to be characteristic in 
NCIPH irrespective of severity of liver disease. They proposed abnormally unresponsive 
hepatic stellate cells as the probable reason for ADAMTS13 deficiency and absence of 
hepatic fibrosis. 
 Based on the above literature on gut disorders and prothrombotic conditions 
among NCIPH patients, we made the following hypothesis. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
Existence of 
prothrombotic state in 
portal circulation due 
to ADAMTS13 
deficiency 
 
Hypothesis 
 
Presence of gut 
disorders which make 
the gut leaky for gut 
derived factors to 
enter the portal 
circulation 
 
Obliterative portal 
microangiopathy 
Leaky gut: 
 The gastrointestinal tract apart from serving its primary functions of digestion and 
absorption plays a major role as a barrier between environment and host. The intestinal 
barrier has mechanical and functional components. The mechanical barrier is formed by 
the intestinal epithelial layer particularly the tight junctions between the epithelial cells, 
mucus coat on the epithelial surface, sub epithelial connective tissue and capillary 
endothelium. Functional barrier is formed by specialized epithelial cells like paneth cells, 
gut associated lymphoid tissue and its immune cells(34,35) 
 The tight junctions are complex and dynamic; they are selectively permeable to 
micromolecules and impermeable to bacteria and macromolecules like 
lipopolysaccharides. They are regulated by variety of stimuli like dietary factors, 
neuronal and humoral stimuli and inflammatory mediators. Gut microbiota play an 
important role in maintaining the integrity of this barrier function.(36) Intestinal 
permeability can be affected by various factors like reactive oxygen species produced as 
a result of reperfusion injury or intestinal inflammation, inflammatory mediators, nitric 
oxide overproduction, Interleukin 6,certain bacteria like E.coli and Klebsiella, alcohol, 
drugs like NSAID etc(7) 
 Leaky gut describes hyperpermeability of intestinal epithelial barrier. Such 
leakiness ultimately results in bacterial translocation which means translocation of 
bacteria or bacterial products across the intestinal barrier(7) 
 It is well documented that gut disorders like inflammatory bowel disease, celiac 
disease, tropical spure can be associated with leaky gut(6,37,38),hence bacterial 
translocation can happen in these conditions(39),(40) 
 Measures of bacterial translocation: 
 Identification of intestinal bacteria in mesenteric lymph nodes (MLNs) is the 
direct evidence of bacterial translocation (BT), however sampling MLNs is difficult. 
Demonstration of intestinal bacteria or its products like endotoxin in portal/ peripheral 
blood is an indirect evidence of BT. Bacterial identification by PCR method is superior to 
culture method(41–43) Amplification of a region of 16s rRNA gene, a conserved 
eubacterial gene is a sensitive method for detection of bacteria(44) 
 Though bacterial translocation can occur in the absence of altered intestinal 
permeability(40), leaky gut is a trigger for bacterial translocation(7,45) Therefore 
measurement of IP( intestinal permeability) can also serve as an indirect measure of 
bacterial translocation. 
 Loss of intestinal integrity can be assessed by various methods(46). Most 
commonly used among those is differential sugar absorption test (DST). This test is based 
on the fact that larger oligosaccharides like lactulose do not permeate through intact 
epithelial barrier, whereas smaller monosaccharides do so. On simultaneous oral 
administration of a large and a small molecular probe, both will enter the circulation 
according to the permeability status following which they will be excreted in urine. 
Measurement of the ratio of recovery in the urine will then give information about the 
paracellular passage. Usage of two compounds and measurement of ratio of recovery 
help to overcome confounding factors like gastric emptying, bacterial degradation, gastric 
dilution, intestinal transit and renal function(36,46) The differential sugar absorption test 
using  Lactulose and  Mannitol  is found to have high sensitivity and specificity in 
assessing small intestinal permeability(47) Other tests used to assess IP are polyethyl 
glycol permeation study and chromium labeled EDTA permeation study.      
 
Clinical relevance of bacterial translocation (BT): 
 Bacterial translocation happens when there is damage to intestinal barrier or when 
there is immune suppression. Berg stated that a baseline translocation in normal 
physiological state may be a boost to the immune system(34) Much evidence exits to 
support bacterial translocation as the cause for infectious complications in critically ill 
patients like trauma, burns, postoperative patients and in patients with multi organ 
dysfunction(48) Spontaneous bacterial peritonitis occurring in cirrhotics is due to 
intestinal bacterial translocation. Selective intestinal decontamination is helpful in 
preventing infectious complications in cirrhotic patients with gastrointestinal hemorrhage 
and low protein ascites. Such measure also prevents SBP recurrence(49) 
 
Bacterial translocation and cirrhosis: 
 There is lots of research conducted with regard to bacterial translocation in 
cirrhosis. Animal studies have shown that detection of bacterial DNA in peripheral fluids 
like ascitic fluid or pleural fluid or blood represent intestinal bacterial translocation(50). 
Studies have shown that around one third of patients with cirrhosis and non neutrocytic 
culture negative ascites have detectable peripheral blood and ascitic fluid bacterial 
DNA(44,51),(52) Its well recognized that the bacterial translocation occurs 
predominantly in advanced cirrhosis. In a study by Bellot et al, peripheral blood bacterial 
DNA was positive in nearly 40% of cirrhotic patients with ascites, but in none among 
those without ascites(8) 
  
Mechanisms of bacterial translocation in cirrhosis: 
 Intestinal hypomotility, stasis and bacterial overgrowth, altered intestinal 
permeability due to oxidative stress at intestinal mucosal level, nitric oxide 
overproduction leading to leaky gut, poor immune response in MLN are all the possible 
mechanisms for bacterial translocation in cirrhosis(49) 
 Scarpellini et al observed a significant association between the advanced liver 
disease and altered intestinal permeability, a direct correlation was noted between 
worsening liver cirrhosis as per child pugh classification and the prevalence of bacterial 
translocation among cirrhotics. 75% of child’s C patients, 39% of child’s B patients and 
22% of child’s A patients were found to have impaired IP(45). 
 
 
     Figure 5: Mechanisms of bacterial translocation in liver cirrhosis 
  
Consequences of bacterial translocation in cirrhosis: 
 Bacterial translocation is considered to be the prime mechanism for infectious 
complications, particularly SBP in cirrhotic patients. Presence of peripheral blood 
bacterial DNA is associated with increased nitric oxide production, peripheral 
vasodilatation, systemic circulatory dysfunction, intrahepatic endothelial dysfunction and 
high levels of proinflammatory cytokines like TNF alpha(8) These changes increase the 
risk of development of hepatorenal syndrome and SBP, ultimately increasing the risk of 
death(53). Bacterial translocation as evident by positive serum and ascitic fluid bacterial 
DNA has been observed to be an independent prognostic marker in non infected patients 
with advanced cirrhosis(52) 
  
Role of bacterial translocation in liver fibrosis: 
 There are recent advanced studies demonstrating the role of Toll like receptors     
(TLRs) in the liver fibrogenesis. Hepatic stellate cells are the prime cell types in liver 
fibrogenesis, they get transformed to myofibroblasts upon stimulation by factors like 
TGFβ and PDGF which are released from the adjacent kupffer cells. In liver disease 
patients, altered intestinal permeability and bacterial translocation can activate the TLRs 
of kupffer cells, endothelial cells and stellate cells as a part of innate immune response. 
This results in potent immune response and activation of stellate cells(9,54) Thus 
bacterial translocation is important in progression of liver fibrosis. 
 Leaky gut and gut derived bacterial products are considered to be of fundamental 
importance in the pathogenesis of Alcoholic liver disease (55) and in Non alcoholic fatty 
liver disease(56) 
 
Bacterial translocation and NCIPH: 
As stated above, NCIPH is found to be associated with various gut disorders and 
such gut diseases can be associated with leaky gut and bacterial translocation. 
Nevertheless, the role of leaky gut and bacterial translocation in the pathogenesis of 
NCIPH has not been studied so far. 
 
 
ADAMTS13: (a disintegrin and metalloprotease with a thrombospondin type 1 
motif, member 13) 
 ADAMTS13 is a metalloprotease, the function of which is to cleave von 
Willebrand factor (VWF) multimers. Congenital or immune mediated deficiency in 
ADAMTS13 activity, reduce or abolish the cleavage of unusually large VWF multimers.  
Ultralarge VWF released from activated endothelial cells would accumulate if the 
protease activity is subnormal. This leads to platelet clumping and thrombi formation 
under high shear stress resulting in microangiopathy characterized by schistocytic 
hemolysis, thrombocytopenia and multiorgan microcirculatory disturbances. 
Thrombotic thrombocytopenia purpura (TTP) is a condition characterized by 
thrombotic microangiopathy due to deficient ADAMTS13. Hereditary TTP is due to 
homozygous/ heterozygous mutation in ADAMTS13 gene whereas acquired TTP is due 
to antibody formation. Even in hereditary TTP, clinical manifestations due to 
microcirculatory disturbance occur only in the presence of triggering factors such as 
pregnancy, infection, drugs, malignancy. Treatment of TTP is plasma exchange with FFP 
which replenishes ADAMTS13(57). 
 ADAMTS13 deficiency can occur in varied clinical situations such as acute 
inflammatory conditions like DIC, post operative period, uremia, liver cirrhosis, other 
thrombocytopenic conditions, late pregnancy, neonatal period, elderly age(58,59). 
However, severe ADAMTS13 deficiency defined as ADAMTS13 activity of  <5% of 
normal is considered to be specific for TTP(60) 
 ADAMTS13 is produced almost exclusively by hepatic stellate cells(10), there is 
high chance that its level of activity will be affected in liver diseases. 
 
ADAMTS13 and cirrhosis: 
 Advancing liver cirrhosis is associated with progressively increasing risk of 
platelet thrombi formation. This is due to the excess production of VWF multimers by 
damaged/ activated sinusoidal endothelial cells during liver injury, which in turn promote 
platelet aggregation. It has been documented that the levels of VWF antigen and activity 
are elevated in liver cirrhosis and the elevation is directly proportionate to the severity of 
the liver disease. The progressive increase in ultralarge VWF multimer is not only due to 
overproduction, but also due to the corresponding reduction in the ADAMTS13 activity 
noted in cirrhosis(11) 
Possible mechanisms for reducing ADAMTS13 activity in cirrhosis are excess 
consumption by large quantities of VWF Ag, inhibition of activity by inflammatory 
cytokines or other inhibitors/ antibodies, decreased production from the stellate cells(61) 
Uemura et al performed a comprehensive analysis of ADAMTS13 activity, 
antigen, VWF activity and multimer levels in 33 patients with chronic hepatitis and 109 
patients with liver cirrhosis. They found that the mean ADAMTS13 activity was 
progressively decreasing with increasing severity of liver disease. In their study group, 
the mean ADAMTS13 activity was 87% in chronic hepatitis, 79% in Child’s A cirrhosis, 
63% in Child’s B cirrhosis, and 31% in Child’s C cirrhosis. Severe deficiency (<3% of 
controls) was noted in five end-stage cirrhosis patients. Plasma inhibitor for ADAMTS13 
was detected in 83% of patients with moderate or severe deficiency. 
The abnormally high VWF Ag: ADAMTS13 activity ratio can cause sinusoidal 
microcirculatory disturbances which lead to progressive liver injury and also contribute 
to multiorgan failure. This phenomenon has been documented in severe alcoholic 
hepatitis(62) and in graft dysfunction following liver transplantation(63) 
Thrombocytopenia observed in advanced liver cirrhosis is multifactorial, 
contributing factors include hypersplenism, low thrombopoietin levels, myelosuppression 
of platelet production by HCV, alcohol. It is also proposed that high levels of Ultralarge 
VWF and platelet aggregation additionally contribute to thrombocytopenia(61)  
 Figure 6: Platelet levels, ADAMTS13 activity and ADAMS13 antigen levels progressively decrease 
with worsening liver disease(11) 
  
  
Recently Ferlitsch at al found VWF Ag level as a good predictor of presence of 
clinically significant portal hypertension, development of decompensation and mortality 
in liver cirrhosis(64) 
 
 
 
 
  
ADAMTS13 and NCIPH: 
 Irrespective of the severity of liver dysfunction, low ADAMTS13 activity was 
noted in 18 NCIPH patients by Mackie et al (12). Severe deficiency which is considered 
to be specific for TTP was also observed in 28% of NCIPH patients. 
 NCIPH is invariably associated with thrombocytopenia which is often attributed 
to hypersplenism, but it can be disproportionate to hypersplenism, hence there is a 
possibility that additional mechanisms exist. Development of portal microangiopathy in 
NCIPH may represent a “localised TTP” happening at the portal microcirculation due to 
low ADAMTS13 activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
METHODOLOGY 
 
 
 
 
 
Study Design:  Case control study 
Study Period:  March 2011 to November 2012 
Study Setting:  Department of Gastrointestinal sciences,  
Christian Medical College. 
 
Study Subjects:  
Cases:  These were patients with liver biopsy proven Non Cirrhotic Intrahepatic Portal 
Hypertension (NCIPH) 
 
Inclusion criteria:  Patients who fulfilled all the following five criteria were included as 
cases. 
1. Presence of portal hypertension as evidenced by any two or more of the 
following- varices, high SAAG ascites, hepatic venous pressure gradient 
more than 5 mm of Hg, cytopenia secondary to hypersplenism, 
2. Patent portal and hepatic veins by Doppler ultrasound,  
3. Liver biopsy consistent with NCIPH i.e. Absence of advanced fibrosis/ 
cirrhosis, 
4. Exclusion of conditions causing chronic liver disease such as viral 
hepatitis, alcoholic hepatitis, metabolic causes like Wilson’s/ 
Hemochromatosis, autoimmune hepatitis, Non alcoholic steatohepatitis, 
5. Conditions that may cause NCIPH like lesions like congenital hepatic 
fibrosis, Sarcoidosis. 
 
 Exclusion criteria: 
1. Patients with recent gastrointestinal bleed 
2. Hepatocellular carcinoma 
3. Active infections 
4. Current antibiotic use 
Controls: These were patients with Hepatitis B or Hepatitis C related chronic liver 
disease with portal hypertension. Diagnosis was made based on serology (a positive 
HBSAg or anti HCV antibody), imaging (Ultrasonography consistent with chronic liver 
disease) and upper GI scopy confirming the presence of varices. Exclusion criteria were 
same as that for cases. 
Consent: Informed consent was taken from all the patients. 
Study protocol was approved by Institutional Review Board (IRB) 
Methods: 
Demographic data: 
  Demographic data like age, gender, residence, socioeconomic status were 
collected from the study subjects. 
Baseline investigations: 
The following are the baseline investigations done in all study subjects. 
1- Etiological workup for chronic liver disease ( Viral serology for hepatitis B and  
C, if negative autoimmune profile that included ANA,SLA,LKM,SMA, Wilson’s 
workup that included 24 hours urine copper and serum ceruloplasmin, Iron 
studies) 
2- Ultrasonography of abdomen to look for liver size, liver space occupying lesion 
3- Doppler to look for portal vein thrombosis, Budd chiari syndrome. 
4- Upper GI scopy to assess varices 
5- Ascitic fluid analysis if ascites was present 
6- Liver biopsy, either percutaneous of transjugular route as indicated. NCIPH was 
diagnosed only in the absence of advanced fibrosis or cirrhosis.( biopsy was done 
only in cases not in controls) 
7- Baseline biochemical investigations like liver function test and renal function test, 
Alpha fetoprotein, Prothrombin time with INR, Complete blood count. 
 
Aim 1: To look for association between gut disorders, bacterial translocation and 
NCIPH. 
Variables chosen: 
1- Assessment of Celiac disease spectrum by testing serum IgA anti 
tissue transglutaminase antibody and duodenal histology. 
2- Intestinal permeability assessment using urinary Lactulose/ Mannitol 
ratio ( an indirect measure of bacterial translocation) 
3- Peripheral blood bacterial DNA quantification by detection of 16S 
rRNA gene using PCR.( a marker of bacterial translocation) 
4- Plasma Tumor necrosis factor (TNF ) alpha levels ( a measure of 
consequence of bacterial translocation) 
Aim 2: To assess the status of ADAMTS13 (a disintegrin and metalloprotease with a 
thrombospondin type 1 motif, member 13) in NCIPH patients and compare with that of 
controls. 
Variables chosen: 
1- Plasma ADAMTS13 activity assay 
2- Plasma ADAMTS13 antigen estimation 
 
 
Celiac disease spectrum: 
Anti tTG antibody: Evaluation of IgA antibody against neo epitopes of tissue 
transglutaminase was performed using commercially available solid phase enzyme 
immuno assay kit (AESKULISA Celichek, Germany and AIDA, Germany) The assay 
employed recombinant human transglutaminase. Quantitative interpretation of patient’s 
sample was obtained in U/ml, titers < 15 U/ml was taken as negative, 15 to 20 as 
borderline and >20 as positive. 
Duodenal histology: Upper gastrointestinal endoscopy was done and duodenal biopsy 
was taken from D2. Celiac enteropathy grading was done based on Marsh grading. 
 
Intestinal permeability testing by urinary L/M ratio: 
After an overnight fast the patient emptied his or her bladder and drank a solution 
containing 2 g mannitol and 5 g lactulose made up to 100 ml with demineralised water. 
For the first 2 hours after drinking the test fluid, no food or fluid was allowed and all the 
urine passed in the 5 hours after they had drunk the test fluid was collected. 
Chlorohexidine digluconate 20% (0.5 ml) was added to the urine as a preservative. The 
urine volume was measured and aliquots were stored frozen at -20°C. To calculate the 
lactulose/mannitol ratio, samples were analyzed for lactulose and mannitol by gas 
chromatography. A lactulose/mannitol ratio ≥0.086 was considered abnormal. 
 
Plasma TNF alpha levels: 
 TNF alpha estimation was done in stored plasma samples using capture ELISA 
method (BD OptEIA
™  
-BD biosciences, San Diego) 
 
Peripheral blood bacterial DNA quantification: 
  Whole blood sample was collected under aseptic precautions into sterile 
vacutainer tubes with EDTA. Plasma samples were centrifuged and DNA was extracted 
by salting method and the precipitate was stored in deep freezer at -20°C until further 
analysis. 
Real time PCR:  
Target gene was 16s rRNA gene, a conserved eubacterial gene. The primer set 
used was 3’-CGGTGAATACGTTCCCGG-5’ and reverse primer 3’- 
TACGGCTACCTTGTTACGACTT-5’. Amplicon size for above mentioned primers was 
145bp (Bioserve Biotechnologies, India). Master mix for PCR assay was from (Ref. No. 
RT-SY2X-03+WOUN) Eurogentec,Belgium. Chromo4 real time PCR detection system 
(Biorad, USA) was used for quantification. Total bacterial levels were expressed as CFU 
per ml of sample and calculated by plotting standard graph against bacterial plasmid 
DNA standards.  
 
 ADAMTS13 activity assay and antigen level measurement: 
 Citrated whole blood sample was collected in vacutainer tubes. Platelet poor 
plasma was separated by centrifugation and aliquoted and frozen at -80 C until assay.  
ADAMTS13 activity assay and antigen level measurement were done using peptide 
substrate chromogenic assay (Technozym  ADAMTS13 ELISA) Normal ADAMTS13 
activity was taken as 60 to150% and normal ADAMTS13 antigen level was taken as 0.48 
to1.59 µg/ml after standardization. 
 
Statistical analysis: 
Sample size: Study design was a case control study. With an assumption that 30% of 
NCIPH patients would have low ADAMTS13 activity and/ or positive peripheral blood 
bacterial DNA PCR and the same in controls would be 5%, we arrived at a sample size of 
35 patients in each group with 80% power and an alpha error of 5% 
Statistical Methods: Continuous variables were expressed in median and range. Man 
Witney U test was used for comparison of continuous variables. Fischer exact test was 
used to compare discrete variables. Spearman correlation coefficient was used for 
assessing correlation between variables. SPSS 15 software was used for analysis, a          
p value of <0.05 was considered significant.  
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RESULTS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Total number of cases:  33 NCIPH patients 
 
Total number of controls:  23 patients with Hepatitis B and 2 patients with Hepatitis C 
related chronic liver disease with portal hypertension. 
 
Demographic data: 
 Median age of NCIPH patients was 36 years (range 21-62) and that of controls 
was 42 years (range 17-63). There were predominantly males in both the groups (21 out 
33 cases and 23 out 25 controls were males). 
 Most of the patients in both the groups were in middle class by modified 
Kuppuswamy’s socioeconomic status scale. 
  
Table 1: Demographics 
 
 
Cases (n=33) Controls (n=25)  p value 
Age in years 
Median ( range) 
36 (21-62) 42 (17-63) 0.097 
Gender (M:F) 21:12 23:2 0.015 
Residence 
Northern India/ Southern 
India/Others 
13/18/2 20/2/3 - 
Socioeconomic   status 
(Upper/Middle/Lower) 
3/23/7 0/17/8 0.352 
 
 
 
  
 
Baseline clinical characteristics: 
 
  Consecutive NCIPH patients were enrolled, whereas HBV/HCV related chronic 
liver disease patients were enrolled based on the Child’s status and MELD score so that 
they matched with the cases. This was done due to the fact that the possibility of bacterial 
translocation increases with increasing severity of liver dysfunction(8,45); same is the 
case with reduction in ADAMTS13 activity(11). So it is essential that the two groups 
match each other in CTP status and MELD score. 
 Most of the patients in both the groups were in Child’s A status (28 out of 33 
cases and 20 out of 25 controls) There were no CTP C patients among cases and so no 
CTP C controls were taken( p value- 0.731) The median MELD score in NCIPH group 
was 10 with a range of 6 to 15. Among controls, the median MELD score was 10 with a 
range of 8 to 16(p value - 0.128) 
 
Table 2: Clinical parameters  
 
Cases 
(n=33) 
Controls 
(n=25) 
 p value 
BMI  
(underweight/normal/ 
overweight/obese) 
3/20/8/2 0/22/3/0 0.683 
Child’s status 
(A/B/C) 
28/5/0 20/5/0 0.731 
MELD score 
Median( range) 
10 (6-15) 10 (8-16) 0.128 
Platelet count  
x 103  /cu.mm 
Median (range) 
62 (29-344) 72 (24-170) 0.85 
BMI: Body Mass Index, MELD: Model for End Stage Liver Disease  
 
 
  
 
 
 There was thrombocytopenia noted in both cases and controls. The median 
platelet count was low in both the groups (62,000/cu.mm and 72,000/cu.mm respectively 
p-0.85). 23 out of 33 cases had platelet less than 1 lakh /cu.mm, totally six NCIPH 
patients had undergone splenectomy in the past, among them 3 had normal platelets; 
three had counts less than 1.5 lakhs. 
 Body mass index was noted to be preserved in most of the patients. Few of the 
NCIPH patients were obese. Three of the cases had diabetes mellitus. 
 
Table 3: Clinical parameters  
 
Cases (n=33) Controls (n=25) 
Ascites 
Present/absent 
5/28 4/21 
Liver size 
Normal/shrunken 
11/22 8/17 
HVPG  
≤5 mm of Hg/ >5 mm of Hg 
7/8  (n-15) nd 
Variceal status 
(bleeder/nonbleeder/ 
novarices) 
17/12/4 8/17/0 
HVPG: Hepatic Venous Pressure Gradient, nd- Not done 
 
 
 Mild ascites was present in five cases and in four controls. None of them had past 
history of spontaneous bacterial peritonitis or large volume paracentesis. Two third of 
NCIPH patients had shrunken liver by ultrasonography. 
 Hepatic venous pressure gradient was measured in 15 NCIPH patients who 
underwent TJLB. Only 7 of them had low HVPG, rest had higher than 5 mm of Hg, the 
maximum HVPG was 15 in one patient. 
  17 out of 33 cases had past history of variceal bleed and that was the clinical 
presentation in most of them. 12 patients had varices without bleed, they were either 
incidentally detected to have varices during endoscopy or they presented with features of 
splenomegaly and hypersplenism. 4 did not have varices, clinical presentation in all of 
them was splenomegaly with or without hypersplenism. All the controls had varices as 
per the inclusion criteria. 8 of them had past history of variceal bleed, rest were non 
bleeders. 
 Serum Immunoglobulin levels were tested in 17 cases and 11 controls. IgG was 
more than upper limit of normal in 11 cases and 10 controls, IgA was more than limit of 
normal in 4 cases and 5 controls. None of the tested patients had immunoglobulin 
deficiency. 
 
 
 
 
 
 
 
 
 
 
 
 Celiac disease spectrum: 
 IgA anti tissue transglutaminase (tTG) antibody was tested in 32 NCIPH patients 
and in 10 controls.  
NCIPH cases: 
Nine cases were positive for the anti tTG antibody; seven of them were subjected 
to UGI scopy and D2 biopsy. Villous atrophy consistent with celiac disease was noted in 
3 out of seven cases, three had non specific chronic duodenitis and the rest one had 
normal duodenal histology. Thus there were a total of 3 patients with celiac disease 
(positive serology and a consistent histology) among the NCIPH patients which accounts 
to 9.4%. There were 4 patients with latent celiac disease (positive serology with an 
inconsistent histology); the positivity may be due to false positive reaction as well which 
was not ruled out by doing IgA anti endomysial antibody. 
Among the 23 cases, those who were negative for anti tTG antibody, duodenal 
histology was available for 8 patients. One of them had mild villous atrophy, four 
duodenal biopsies were normal; three were showing non specific duodenitis. 
     
A          B 
 
 
 
 
 
 
Figure 7: Duodenal histology A- anti tTG positive NCIPH patients and B- anti tTG negative NCIPH 
patients. 
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 Figure 8: Celiac disease spectrum in NCIPH patients 
 
Effect of gluten free diet: 
 All the three celiac disease patients were advised gluten free diet, anti tTG 
became negative on follow up for 2 patients, for the third patient, titer came down from 
1412 IU/ml to 117.5 IU/ml. Two of the three latent celiac disease patients with duodenal 
biopsy showing chronic duodenitis were also on gluten free diet with which anti tTG 
antibody became negative in both of them. 
Study controls: 
Out of the 10 controls tested for anti tTG antibody, three were positive for the Ab. 
However duodenal biopsy was not taken in these patients. Only one of these three 
patients had serum immunoglobulin tested and was having hypergammaglobulinemia. 
LATENT CELIAC 
or FALSE + ve 
CELIAC DISEASE 
9.4% 
 Intestinal permeability testing by L/M ratio: 
 Assessment of intestinal permeability by dual sugar absorption test using 
Lactulose and Mannitol was performed in 26 cases (CTP A- 24, B-2) and 16 controls      
(CTP A-13, B- 3). In both the groups nearly 20% had abnormal intestinal permeability. 
The five NCIPH patients and three controls those who had abnormal IP were all in CTP 
A status and none of them had ascites. The test was invalid in three NCIPH cases due to 
coexistent glycosuria which made interpretation difficult. 
 Out of the three celiac disease patients, only one had L/M ratio tested and 
that was abnormal.      
             
 
 
 
 
 
 
 
 
 
 
 
Tested in 26/33 NCIPH cases                             Tested in 16/25 Controls 
  Invalid result- 3                               Normal- 13 
  Normal- 18                                      Abnormal- 3 
  Abnormal- 5 
Figure 9: Intestinal permeability in cases and controls  
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 Table 4: Characteristics of patients with abnormal L/M ratio 
 
Cases (n=5) Controls (n=3) 
Child’s status (A/B/C) 5/0/0 3/0/0 
MELD score  
Median ( range) 
10(8-11) 11(9-11) 
Anti tTG antibody 
(positive/ negative) 
2/3 1/2 
Duodenal 
histology 
Not done/ 
normal 
2 3 
Chronic 
duodenitis 
2 0 
Villous atrophy 
1 0 
MELD: Model for End stage Liver Disease, tTG- tissue trans glutaminase 
 
Peripheral blood bacterial DNA by PCR: 
 Due to technical difficulties PCR for detection of 16s rRNA gene could not be 
done. We encountered contamination and so all the samples including the no template 
controls (NTC) tested positive for bacterial DNA in unacceptably high colony forming 
units attributable to contamination. However, we could not find out the exact source of 
such bacterial contamination. So the test could not be standardized. 
 
Plasma TNF alpha levels: 
 TNF alpha estimation was performed in plasma samples of 31 cases and 24 
controls by ELISA method (BD OptEIA
™ ). TNF α was not detectable in any of the 
samples. 
 
 
 ADAMTS13: 
 ADAMTS13 activity assay by chromogenic ELISA and estimation of 
ADAMTS13 antigen levels by ELISA was done in a group of cases and controls. 
 
ADAMTS13 activity assay: 
 Assay was done in 20 NCIPH cases and in 13 controls. Most of them were in 
Child’s A status, two in each group were in Child’s B status. Both the groups were 
comparable with regard to the Child’s status and MELD score. 
 
 
Table 5: Clinical parameters of patients tested for ADAMTS13 activity 
 
Cases (n=20) Controls (n=13) 
Child’s status  
(A/B/C) 
18/2/0 11/2/0 
MELD score  
Median ( range) 
9(7-13) 11(8-16) 
Platelet count*  
x 103  /cu.mm 
Median (range) 
61 (29-255) 61 (24-160) 
* Three patients were post splenectomy patients. 
 
Results: 
Normal range of ADAMTS activity is 60 -150% for our lab. Activity less than 
60% is low, if it is less than 5% it is taken as severely low.  
 
 
 
Significantly low ADAMTS13 activity in cases than controls: 
  15 out of 20 cases were found to have low ADAMTS13 activity( 75% of cases) , 
rest 5 had normal activity( 25% of cases).Whereas among controls, only 4 had low 
activity (31%) and the rest 9 had normal activity(69%){ Figure-10} 
   
Table 6: ADAMTS13 activity in cases and controls 
Variable Cases (n=20) Controls (n=13)  p value 
ADAMTS 13 activity  
(% of normal) 
Median (range) 
44 (2-104) 
 
104 (2-104) 
 
0.04 
ADAMTS 13 activity in 
Child’s A patients 
Median( range) 
42.9 (2-104) 
n= 18 
104 (2-104) 
n= 11 
0.02 
ADAMTS 
13 activity  
<20% 
6 (30%) 3 (23.1%) 
0.03 
20-39% 
1 (5%) 0 
40-59% 
8 (40%) 1 (7.7%) 
60-150% 
5 (25%) 9 (69.2%) 
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Figure 10: ADAMTS13 activity in cases and controls 
         
 
p- 0.03 
   Median ADAMTS13 activity among cases was 44% with a range of 2 to 104%, 
Median ADAMTS13 activity among controls was 104% with a range of 2 to 104%. The 
difference was statistically significant (p value- 0.04) (Figure 11}               
         
 
Distribution of low activity among cases was in such a way that nearly half of 
them had mild reduction in activity – 8 patients out the 15 had activity in the range of 40 
to 60%. On the other hand 6 patients had very low activity of <20%, 2 among them had 
severely low activity of <2%. Both the patients with severely low activity were in Child’s 
A status. {Figure 12}  
 
 
   
 
 
 
 
 
 
Figure 11: ADAMTS13 activity in cases and controls 
         
 
Figure 12: Distribution of ADAMTS13 activity in cases and controls 
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Significantly low ADAMTS13 activity in Child’s A NCIPH patients vs. Child’s A 
controls 
 
 Its well documented in literature that with advancing severity of liver dysfunction, 
plasma ADAMTS13 activity will decrease proportionately in cirrhotic patients(11)which 
implies that patients with early liver disease i.e. those in Child’s A status are expected to 
have normal or only marginal reduction in ADAMTS activity. 
We analyzed the data for Child’s A patients alone and we found the ADAMTS13 
activity to be significantly low among the cases when compared to controls.  
Median ADAMTS13 activity among cases (n=18) was 42.9% with a range of 2 to 
104%. Median ADAMTS13 activity among controls (n=11) was 104% with a range of 2 
to 104%. The difference was statistically significant (p value- 0.02) (Figure 13}               
 
   
 
 
 
Figure 13: ADAMTS13 activity in cases and controls with Child’s A 
liver disease 
         
 
 Among the CTP A patients, 14 out of 18 cases had low ADAMTS13 activity, 
whereas only 2 out of 11 controls had low activity (77.8% vs. 18.2% p value- 0.005) 
 
ADAMTS13 antigen assay: 
 Assay was done in 25 NCIPH cases and 16 controls. Most of them were in 
Child’s A status, four in each group were in Child’s B status. Both the groups were 
comparable with regard to the Child’s status and MELD score. 
 
Table 7: Clinical parameters of patients tested for ADAMTS13 antigen 
 
Cases (n=25) Controls (n=16) 
Child’s status  
(A/B/C) 
21/4/0 12/4/0 
MELD score  
Median ( range) 
10(6-15) 11(8-16) 
Platelet count*  
x 103  /cu.mm 
Median (range) 
62 (29-344) 61 (24-160) 
* Five patients were post splenectomy patients. 
 
Results: 
Normal range of ADAMTS antigen level is 0.48 to1.59 µg/ml for our lab.  
 
Significantly low ADAMTS13 antigen level in cases than controls: 
23 out of 25 cases were found to have low ADAMTS13 antigen( 92% of cases) , 
only 2 had normal antigen( 8% of cases).Whereas among controls, only 7 had low 
antigen(44%) and the rest 9 had normal antigen(56%){ Figure-14} 
 
  
 
 
 
 
 
 
 
 
Median ADAMTS13 antigen level among cases was 0.14 µg/ml with a range of 
0.02 to 0.77 µg/ml. Median ADAMTS13 antigen level among controls was 0.54 µg/ml 
with a range of  0.02 to 1.43 µg/ml   The difference was statistically significant (p value- 
0.004) (Figure 15}            
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Figure 14: ADAMTS13 antigen levels in cases and controls 
         
 
Figure 15: ADAMTS13 antigen levels in cases and controls 
         
 
  
Significantly low ADAMTS13 antigen in Child’s A NCIPH patients vs. Child’s A 
controls 
 
 The ADAMTS13 antigen level among the NCIPH patients in Child’s A status was 
compared with that of the controls in Child’s A status. Median antigen level among cases 
(n=21) was 0.17 µg/ml, range 0.02 to 0.77 µg/ml. Median antigen level among controls    
(n=12) was 0.6 µg/ml, range 0.68 to 1.13 µg/ml. The difference was statistically 
significant (p value- 0.001) 
 
No significant correlation between ADAMTS13 activity and MELD score in both cases 
and controls: 
 Correlation between ADAMTS13 activity and MELD score was calculated both 
in cases and controls using spearman correlation coefficient test. There was no significant 
correlation noted in both the groups (cases -spearman ρ=0.119, p value=0.617, controls -
spearman ρ= -0.089, p value=0.773) 
 
No significant correlation between ADAMTS13 activity and HVPG: 
 Correlation between ADAMTS13 activity and HVPG was calculated for cases 
with available HVPG, using spearman correlation coefficient test. There was no 
significant correlation noted (spearman ρ=0.125, p value-0.715) 
 
 
  
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 The present study is a case control study to look for association between bacterial 
translocation and NCIPH. The study also aimed at assessing the ADAMTS13 activity in 
NCIPH patients. The study was initiated with a hypothesis that in NCIPH, underlying gut 
disorders and the resulting bacterial translocation trigger microangiopathy in the presence 
of low ADAMTS13 activity in the portal microcirculation. 
 We observed a high prevalence of celiac disease among NCIPH patients when 
compared to the general population. Population studies in India have shown prevalence 
of celiac disease in general population to be ranging from 0.3 to 1%(65,66), whereas in 
our study subjects, we found a 9.4% prevalence of celiac disease among the cases. This 
high prevalence of celiac disease is consistent with the findings of Eapen at al who 
documented 16% prevalence of celiac disease among NCIPH patients(4). 
 Anti tTG antibody positivity was about 30% in both NCIPH patients and in 
controls. Vecchi et al and Villalta et al documented a high prevalence of anti tTG 
positivity (upto 33%) among liver disease patients(67,68). They found the positivity to be 
generally false positive, partly related to hypergammaglobulinemia and associated with 
more advanced liver disease. This may explain the positive results of anti tTG antibody 
among our control group. In a previous study from our centre, 59 patients with hepatitis 
B or hepatitis C related chronic liver disease were tested for anti tTG antibody and 16 out 
of 59 were found to be positive (27%), a total of 28 underwent duodenal biopsy and none 
of them had villous atrophy. It is less likely for the positive serology to be false positive 
among NCIPH cases, since we were able to document villous atrophy in 3 out of 7 
patients who were positive for celiac serology. On gluten free diet, anti tTG antibody  
 became negative in four patients, and in one another patient there was a significant 
reduction in titer. 
 One of the NCIPH patients negative for anti tTG antibody had mild villous 
atrophy in duodenal biopsy. This suggests there may be other gut disorders associated 
with NCIPH. Though there are many hypotheses for the pathogenesis of NCIPH, the 
exact etiology is unknown. The current study is in favor that gut disorders may be yet 
another association with NCIPH and to be looked for in this group. 
 Gut disorders are commonly associated with altered intestinal 
permeability(6,37,38) which in turn can lead to bacterial translocation(7). So we decided 
to look for evidence to support bacterial translocation in NCIPH patients. Generally 
demonstration of peripheral blood bacterial DNA by PCR method is considered to be the 
marker of bacterial translocation(44). Measurement of intestinal permeability by 
Lactulose/ Mannitol ratio testing is a sensitive and a specific marker of leaky gut and this 
can serve as an indirect measure for bacterial translocation(7). Presence of peripheral 
blood bacterial DNA is commonly associated with high levels of inflammatory markers 
like TNF alpha and interleukin 6(51), so we also looked for plasma TNF alpha levels in 
cases and controls. 
 Due to technical difficulties, peripheral blood bacterial DNA estimation was not 
accomplished in our study subjects. This was due to possible contamination leading to 
false positive results which was due to the high sensitive nature of the test method used. 
It is a widely accepted fact that, to maintain high sensitivity and specificity together in 
bacterial DNA estimation by PCR is challenging(69)  
  We observed a reasonably preserved intestinal permeability in both cases and 
controls. Nearly 20% of study subjects had high L/M ratio (≥0.086). Among controls, this 
is consistent with previous reports. Scarpellini et al demonstrated altered intestinal 
permeability among liver cirrhosis patients, in the range of about 20% in CTP A, 40% in 
CTP B and 75% in CTP C patients(45). In our study controls, most of them were in CTP 
A status (13 out of 16 patients) and so a 20% prevalence of abnormal intestinal 
permeability is acceptable. Among NCIPH patients, there is no available data on altered 
intestinal permeability. Celiac disease is generally accepted to have abnormal IP; Cobden 
et al demonstrated that L/M ratio testing has a sensitivity and accuracy as a screening test 
to detect celiac disease(6). In our study cases, only one of the three celiac disease patients 
underwent L/M ratio testing and was found to have abnormal test result.  There were four 
more NCIPH cases with abnormal IP, 2 of them had chronic duodenitis in D2 biopsy. 
The reason for altered IP among NCIPH needs evaluation. This may be due to gut disease 
other than celiac disease. 
 We hypothesized an association between bacterial translocation and NCIPH, and 
we considered leaky status of the gut to be the cause for bacterial translocation. However 
we were not able to demonstrate a higher prevalence of abnormal IP among our study 
cases. Mechanisms of bacterial translocation include intestinal bacterial overgrowth, 
leaky gut and poor immune response(34,49,70) There may be additional contributors for 
bacterial translocation, however disappointingly we were not able to look for peripheral 
blood bacterial DNA to document bacterial translocation. 
 We also looked for TNF alpha levels, and we found it to be undetectable in both 
cases and controls. If it was high among the NCIPH patients, it would have supported the 
association between bacterial translocation and the disease.  
 Most important finding of the present study is the significantly low plasma 
ADAMTS13 activity and antigen levels among NCIPH patients when compared to 
hepatitis B/C related chronic liver disease patients. Uemura et al found a declining 
ADAMTS13 activity with worsening liver dysfunction among liver cirrhosis patients(11) 
However this does not explain the low ADAMTS13 activity among NCIPH patients 
without severe liver disease as per MELD score. Maximum MELD score among cases 
tested for ADAMTS13 activity was 13 and 75% of cases had low activity. When we 
excluded patients with Child’s B status and analyzed the data for Child’s A cases and 
controls, we found a significantly low ADAMTS13 activity and antigen among cases. 
Two patients with severely low activity of <2% were in CTP A status. 
  Above findings with regard to ADAMTS13 and NCIPH is consistent with that of 
Mackie et al(12). In the study by Mackie et al, 18 NCIPH patients were compared with 
matched controls. Low ADAMTS activity was noted in all the cases and the median 
value was significantly lower than the controls. The authors were successful in 
demonstrating the deficiency using multiple methods of ADAMTS assay. In this study 
there was a trend towards inverse correlation between ADAMTS levels and MELD score. 
In our study we found no correlation between ADAMTS13 levels and MELD score/ 
HVPG. 
 Severely low ADAMTS13 activity of <5% of normal is generally considered to 
be specific for TTP(60) However similar severe deficiency can happen in advanced end 
stage liver cirrhosis as shown by Uemura et al. Herein we document severely low activity 
among NCIPH patients with well preserved liver function. This early occurrence of low 
ADAMTS13 activity suggests it to be a cause rather than an effect of the disease. The 
causes for low ADAMTS13 activity can be either decreased synthesis or rapid clearance 
or presence of inhibitors. Mackie et al looked for presence of antibodies/ inhibitors to 
ADAMTS13 and did not detect any significant factors. They also observed that after 
infusing FFP, there was a rise in ADAMTS13 activity with a good half life suggesting 
there is no rapid clearance happening. Authors proposed the cause for low ADAMTS13 
activity to be due to synthetic dysfunction. Abnormally unresponsive stellate cells may be 
responsible for the low ADAMTS13 activity and the absence of hepatic fibrosis. 
 Constitutive low expression of ADAMTS13 would result in lowest ADAMTS13 
levels in portal circulation making the portal vasculature at risk for microthrombi 
formation. In such a situation, when ultralrge vWF multimers are exposed at the surface 
of damaged endothelium, platelet aggregation and microangiopathy set in. Endothelial 
injury is more likely to be due to gut derived factors since the pathology is confined to 
portal circulation. 
 Abnormal vWF :ADAMTS ratio is documented to be important in the progression 
of liver injury in various conditions like acute on chronic liver failure, graft dysfunction 
following liver transplantation and in alcoholic liver disease(62,63) Whereas in NCIPH, 
the abnormal ratio may be the initiating factor in the pathogenesis.  
 
 
 
  
  
 
 
 
 
 
 
 
 
 
CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
  Most of the NCIPH patients had shrunken liver by imaging and almost half of 
them had a high HVPG suggesting that liver biopsy is essential to differentiate 
NCIPH from cryptogenic cirrhosis. 
 Prevalence of celiac disease among NCIPH patients was noted to be 9.4% which 
is much higher than that reported among general population (upto 1%) 
 Intestinal permeability was preserved in majority of patients both among cases 
and controls 
 There was no rise in plasma TNF alpha levels both in cases and controls 
 ADAMTS13 activity was found to be significantly low in NCIPH patients than in 
controls 
 ADAMTS13 antigen level was found to be significantly low in NCIPH patients  
than in controls 
 Among patients with compensated liver disease (CTP A status) there was a 
significantly low ADAMTS13 activity and antigen level among NCIPH patients 
in comparison with controls. 
 There was no correlation between ADAMTS13 activity and MELD score or 
HVPG. 
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Performa  
 
 
 
 
Name: 
 
Age: 
 
Sex: 
 
Contact Address: 
 
Email: 
 
Phone No.: 
 
Hospital No.: 
 
Height: 
 
Weight: 
 
BMI: 
 
Kuppusamy’s Socio economic score: 
 
Case/Control: 
 
Diagnosis: 
 
 
 
 
 
 
  
 
 
 
 
 
Ascites: 
 
CTP score: 
 
MELD score: 
 
UGI scopy(Variceal status): 
 
USG abdomen: 
 
Bacterial DNA: 
 
     Peripheral blood: 
 
     Ascitic Fluid: 
 
L/M ratio: 
 
ADAMTS13 level: 
 
VWF level: 
 
Liver Biopsy: 
 
Liver Biopsy report: 
 
 
 
 
 
 
 
 
  
 
For Cases: 
 
1. Viral Markers: 
HBSAg: 
      HCV antibody: 
      Total Core: 
 
2. Significant Alcohol history:  
 
3. Anti TTG antibody: 
 
 
4. ANA: 
 
5. Immunoglobulins: 
 
6. Ferritin: 
 
7. Ceruloplasmin: 
 
8. Sugars: 
          AC: 
          PC: 
 
9. Lipid profile:  
 Total Cholesterol: 
        Triglycerides: 
 HDL: 
 LDL: 
 
10. Doppler of hepatic veins/ IVC: 
 
11. Vitamin B12 level: 
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Controls: 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
  
 
 
 
 
